Molecular Partners AG was incorporated in Switzerland on November 22, 2004. The company is a clinical-stage biopharmaceutical company applying its groundbreaking DARPin product candidates to the treatment of serious diseases, with a current focus on infectious diseases, oncology and ophthalmology. The company's DARPin platform is designed using anchor protein repeats, allowing the company to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially providing patients with products with higher efficacy and fewer adverse events. 

Molecular Partners reported a GAAP EPS of -CHF0.70 for 1H. The company's cash position stood at CHF 67.9 million as of June 30, 2026, which is expected to fund operations into late 2027.

Molecular Partners

Molecular Partners Reports Q1 GAAP EPS of -CHF0.70, Cash Position at CHF 67.9mln

Molecular Partners AG: cash position of CHF 67.9 million as of June 30, 2026, expected to fund operations into late 2027

Molecular Partners AG: cash position of CHF 67.9 million as of June 30, 2026, expected to fund operations into late 2027

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has maintained its previously reported full-year 2025 forecast for total operating expenses, aligning with its guidance of CHF 55–65 million at constant exchange rates. The company’s 2025 Annual Report, published in March 2026, confirmed that <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">operating expenses amounted to CHF 58.1 million</a>, within the projected range. This figure reflects a <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">reduction from CHF 66.2 million</a> in operating expenses reported in 2024, indicating a continued focus on cost management amid ongoing clinical development activities.The company’s operating expenses in 2025 were primarily driven by research and development (R&amp;D) costs, which <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">decreased from CHF 48.6 million</a> in 2024. Selling, general, and administrative (SG&amp;A) expenses also <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">declined to CHF 15.2 million</a> from CHF 17.6 million in the prior year. Additionally, <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">restructuring expenses of CHF 2.7 million</a> were incurred in 2025 as part of a strategic review aimed at improving operational efficiency.Despite a net financial loss of CHF 3.5 million in 2025—compared to a net financial gain of CHF 7.2 million in 2024—the company reported a <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">net loss of CHF 61.7 million</a> for the year, slightly higher than the CHF 54.0 million net loss in 2024. The company’s cash and cash equivalents, including short-term time deposits, <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">stood at CHF 93.1 million</a> as of December 31, 2025, down from CHF 149.4 million at the end of 2024. However, the company noted that its <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">current financial position is sufficient</a> to fund operations until 2028.Looking ahead, Molecular Partners expects total operating expenses for 2026 to range between CHF 45–55 million, with <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">approximately CHF 6 million attributed</a> to non-cash costs. The company remains focused on advancing its pipeline of DARPin therapeutics, including its lead Radio-DARPin candidate MP0712 and the multi-specific T cell engager MP0533, while <a href="https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-highlights-and-financial-results-full">maintaining a disciplined approach</a> to financial management.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1d08b1e636171002.png" alt="Molecular Partners AG: Maintains previously reported FY forecast total operating expenses">

Molecular Partners AG: Maintains previously reported FY forecast total operating expenses

Molecular Partners announced a Phase 2 study of MP0317 in combination with chemoimmunotherapy for advanced biliary tract carcinoma. The randomized, multicenter study is expected to enroll 75 patients, with a data update in 2027 and completion targeted for 2028. The study aims to explore MP0317's potential to improve treatment options for cholangiocarcinoma patients.Molecular Partners has initiated a Phase 2 clinical trial evaluating MP0317 in combination with chemoimmunotherapy for patients with advanced biliary tract carcinoma. The randomized, multicenter study is designed to enroll 75 participants and will assess the safety and efficacy of the treatment regimen [1]. A data update is anticipated in 2027, with the study expected to conclude in 2028. The trial aims to investigate whether MP0317 can enhance therapeutic outcomes for individuals with cholangiocarcinoma, a rare and aggressive form of cancer with limited treatment options [1]. The development of novel therapies in oncology remains a key focus for biopharmaceutical companies, with clinical trial progress often influencing investor sentiment and market valuation. As the trial progresses, stakeholders will closely monitor interim results and regulatory developments for insights into the drug’s potential commercial viability and impact on the oncology treatment landscape.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cd55a9cdf34d002.png" alt="Molecular Partners' MP0317 Shows Promise in Cholangiocarcinoma Study">

Molecular Partners' MP0317 Shows Promise in Cholangiocarcinoma Study

Molecular Partners announces dosing of first patients in Phase 2 TACTIC study for advanced biliary tract carcinoma. The randomized, multicenter study aims to recruit 75 patients with a 2-to-1 design and is expected to complete in 2028. Data update expected in 2027. Trial-in-progress poster to be presented at ESMO 2026 in October.Molecular Partners has announced the initiation of patient dosing in its Phase 2 TACTIC study for the treatment of advanced biliary tract carcinoma. The randomized, multicenter clinical trial is designed to enroll 75 patients and follows a 2-to-1 randomization ratio. The study is expected to conclude in 2028, with an <a href="https://example.com">interim data update anticipated</a> in 2027. A trial-in-progress poster will be presented at the European Society for Medical Oncology (ESMO) Congress in October 2026, offering an <a href="https://example.com">update on the ongoing research</a>. The TACTIC study represents a key milestone in the company’s oncology pipeline and could provide further insights into the therapeutic potential of its DARPin platform in solid tumors. Investors and stakeholders are likely to monitor the trial’s progress and the timing of data releases for potential implications on the company’s long-term strategy and valuation.

MOLN News